Open AccessImpact of renin–angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis of from the PARTNER 2 trial and registries
Author(s) -
Shmuel Chen,
Björn Redfors,
Tamim Nazif,
Ajay J. Kirtane,
Aaron Crowley,
Ori BenYehuda,
Samir Kapadia,
Matthew Finn,
Sachin S. Goel,
Brian R. Lindman,
Maria Alu,
Katherine H. Chau,
Vinod H. Thourani,
Torsten Vahl,
Pamela S. Douglas,
Susheel Kodali,
Martin B. Leon
Publication year - 2019
Publication title -
european heart journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.336
H-Index - 293
eISSN - 1522-9645
pISSN - 0195-668X
DOI - 10.1093/eurheartj/ehz769
Subject(s) - medicine , hazard ratio , cardiology , propensity score matching , proportional hazards model , stenosis , aortic valve stenosis , aortic valve replacement , ace inhibitor , valve replacement , angiotensin converting enzyme , blood pressure , confidence interval
Left ventricular pressure overload is associated with activation of the cardiac renin-angiotensin system, which may contribute to myocardial fibrosis and worse clinical outcomes. We sought to assess the association between treatment with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) at baseline and clinical outcomes in patients with symptomatic, severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) in the PARTNER 2 trial and registries.